P1472: INTERIM RESULTS OF SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS FROM AN ONGOING OPEN-LABEL STUDY INVESTIGATING FTX-6058 IN ADULTS LIVING WITH SICKLE CELL DISEASE

• P. Bruno,
• J. Kanter,
• J. Ziegler,
• B. Stuart,
• J. Ahn,
• J. Dunn,
• G. Allen,
• C. Morabito

Affiliations

P. Bruno

1 Fulcrum Therapeutics, Inc., Cambridge

J. Kanter

2 University of Alabama Medical Center, Birmingham, United States of America

J. Ziegler

1 Fulcrum Therapeutics, Inc., Cambridge

B. Stuart

1 Fulcrum Therapeutics, Inc., Cambridge

J. Ahn

1 Fulcrum Therapeutics, Inc., Cambridge

J. Dunn

1 Fulcrum Therapeutics, Inc., Cambridge

G. Allen

1 Fulcrum Therapeutics, Inc., Cambridge

C. Morabito

1 Fulcrum Therapeutics, Inc., Cambridge